Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.

Authors: Papadopoulou, Eirini, Rigas, George, Fountzilas, Elena, Boutis, Anastasios, Giassas, Stylianos, Mitsimponas, Nikolaos, Daliani, Danai, Ziogas, Dimitrios C, Liontos, Michalis, Ramfidis, Vasileios, Christophilakis, Charalampos, Matthaios, Dimitris, Floros, Theofanis, Florou-Chatzigiannidou, Chrysiida, Agiannitopoulos, Konstantinos, Meintani, Angeliki, Tsantikidi, Aikaterini, Katseli, Anastasia, Potska, Kevisa, Tsaousis, Georgios

Source: JCO Precision Oncology; 12/1/2024, Vol. 8, p1-8, 8p

Subject Terms: BRAF genes, GENETIC testing, CANCER susceptibility, NUCLEOTIDE sequencing, ENDOMETRIAL cancer, HEREDITARY nonpolyposis colorectal cancer, DNA mismatch repair

The Clinical and Genetic Landscape of Hereditary Cancer: Experience from a Single Clinical Diagnostic Laboratory.

Authors: TSOULOS, NIKOLAOS, AGIANNITOPOULOS, KONSTANTINOS, POTSKA, KEVISA, KATSELI, ANASTASIA, NTOGKA, CHRISTINA, PEPE, GEORGIA, BOUZARELOU, DIMITRA, PAPATHANASIOU, ATHANASIOS, GRIGORIADIS, DIMITRIOS, TSAOUSIS, GEORGIOS N., GOGAS, HELEN, TROUPIS, THEODORE, PAPAZISIS, KONSTANTINOS, NATSIOPOULOS, IOANNIS, VENIZELOS, VASSILEIOS, AMARANTIDIS, KYRIAKOS, GIASSAS, STYLIANOS, PAPADIMITRIOU, CHRISTOS, FOUNTZILAS, ELENA, STATHOULOPOULOU, MAROULIO

Source: Cancer Genomics & Proteomics (1109-6535); Sep/Oct2024, Vol. 21 Issue 5, p448-463, 16p

Subject Terms: NUCLEOTIDE sequencing, GENETIC testing, FAMILY history (Medicine), CANCER patients, PROSTATE cancer, OVARIAN cancer

Polygenic Risk Score (PRS) Combined with NGS Panel Testing Increases Accuracy in Hereditary Breast Cancer Risk Estimation.

Authors: Tsoulos, Nikolaos, Papadopoulou, Eirini, Agiannitopoulos, Konstantinos, Grigoriadis, Dimitrios, Tsaousis, Georgios N., Bouzarelou, Dimitra, Gogas, Helen, Troupis, Theodore, Venizelos, Vassileios, Fountzilas, Elena, Theochari, Maria, Ziogas, Dimitrios C., Giassas, Stylianos, Koumarianou, Anna, Christopoulou, Athina, Busby, George, Nasioulas, George, Markopoulos, Christos

Source: Diagnostics (2075-4418); Aug2024, Vol. 14 Issue 16, p1826, 12p

Subject Terms: GENETIC risk score, ETIOLOGY of diseases, FAMILY history (Medicine), DISEASE risk factors, GENETIC variation

Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic Testing.

Authors: Agiannitopoulos, Konstantinos, Potska, Kevisa, Katseli, Anastasia, Ntogka, Christina, Tsaousis, Georgios N., Pepe, Georgia, Bouzarelou, Dimitra, Tsoulos, Nikolaos, Papathanasiou, Athanasios, Ziogas, Dimitrios, Venizelos, Vassileios, Markopoulos, Christos, Iosifidou, Rodoniki, Karageorgopoulou, Sofia, Giassas, Stylianos, Natsiopoulos, Ioannis, Papazisis, Konstantinos, Vasilaki-Antonatou, Maria, Psyrri, Amanta, Koumarianou, Anna

Source: Cancers; Nov2023, Vol. 15 Issue 21, p5218, 10p

Subject Terms: SEQUENCE analysis, FAMILIES, GENETIC testing, GENETIC variation, CANCER patients, RISK assessment, CANCER genes, DESCRIPTIVE statistics, DISEASE susceptibility, COMMUNICATION, GENETIC counseling, BREAST tumors

Copy Number Variations (CNVs) Account for 10.8% of Pathogenic Variants in Patients Referred for Hereditary Cancer Testing.

Authors: AGIANNITOPOULOS, KONSTANTINOS, PEPE, GEORGIA, TSAOUSIS, GEORGIOS N., POTSKA, KEVISA, BOUZARELOU, DIMITRA, KATSELI, ANASTASIA, NTOGKA, CHRISTINA, MEINTANI, ANGELIKI, TSOULOS, NIKOLAOS, GIASSAS, STYLIANOS, VENIZELOS, VASSILEIOS, MARKOPOULOS, CHRISTOS, IOSIFIDOU, RODONIKI, KARAGEORGOPOULOU, SOFIA, CHRISTODOULOU, CHRISTOS, NATSIOPOULOS, IOANNIS, PAPAZISIS, KONSTANTINOS, VASILAKI-ANTONATOU, MARIA, KABLETSAS, ELEFTHERIOS, PSYRRI, AMANTA

Source: Cancer Genomics & Proteomics (1109-6535); Sep/Oct2023, Vol. 20 Issue 5, p448-455, 8p

Subject Terms: CANCER susceptibility, GENETIC variation, PANEL analysis, NUCLEOTIDE sequencing, OVARIAN cancer, DELETION mutation

A Phase II Trial of Erlotinib As Front-Line Treatment in Clinically Selected Patients With Non–Small-Cell Lung Cancer

Authors: Pallis, Athanasios G., Voutsina, Alexandra, Kentepozidis, Nikolaos, Giassas, Stylianos, Papakotoulas, Pavlos, Agelaki, Sofia, Tryfonidis, Kostas, Kotsakis, Athanasios, Vamvakas, Lambros, Vardakis, Nikolaos, Georgoulias, Vassilis

Source: In Clinical Lung Cancer March 2012 13(2):129-135

Second-line Paclitaxel/Carboplatin Versus Vinorelbine/Carboplatin in Patients Who Have Advanced Non–Small-Cell Lung Cancer Pretreated With Non–Platinum-Based Chemotherapy: A Multicenter Randomized Phase II Study

Authors: Pallis, Athanasios G., Syrigos, Kostas, Kotsakis, Athanasios, Karachaliou, Niki, Polyzos, Aris, Chandrinos, Vassilis, Varthalitis, Ioannis, Christophyllakis, Charalambos, Ardavanis, Alexandros, Vamvakas, Lambros, Vardakis, Nikolaos, Saridaki, Zacharenia, Samonis, George, Giassas, Stylianos, Georgoulias, Vassilis, Agelaki, Sophia

Source: In Clinical Lung Cancer March 2011 12(2):100-105

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.

Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer.

Authors: Xenidis N, Vardakis N, Varthalitis I, Giassas S, Kontopodis E, Ziras N, Gioulbasanis I, Samonis G, Kalbakis K, Georgoulias V, Xenidis, Nikolaos, Vardakis, Nikolaos, Varthalitis, Ioannis, Giassas, Stylianos, Kontopodis, Emmanouel, Ziras, Nikolaos, Gioulbasanis, Ioannis, Samonis, George, Kalbakis, Kostas, Georgoulias, Vassilis

Source: Cancer Chemotherapy & Pharmacology; Jul2011, Vol. 68 Issue 1, p63-68, 6p